doctors MMA’s president shares the reasons why Malaysia is ranked today third in terms of healthcare quality, with a very efficient public system, high quality doctors and strong government support. However, the situation could change as too many doctors change to the private sector, NCDs are drastically increasing and financing healthcare…
IMS IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also shares the opportunities present for pharma companies to invest in Malaysia. IMS is now providing data for the…
Aspen Aspen Malaysia’s country manager details the company’s success in the country with a specific business model based on acquiring and remarketing originators. Although Aspen is a renowned generic player, market dynamics have pushed the company in a different direction until today in Malaysia. Malaysia only became one of Aspen’s…
Sandoz The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics. Could you please give us a broad overview of the generics market in Argentina over the last decade? The dynamics of the generic…
similars The vice president of Laboratorios Beta discusses the factors of why his organization is on the way to consolidating its different business lines and becoming a pure pharmaceutical company. 2014 marks the 74th anniversary of Laboratorios Beta. To what extent is the company today still the same company…
chamber of commerce MGCC’s Executive Director discusses the opportunities and challenges for German pharma and healthcare companies to invest in Malaysia, at a time where most have decided to invest and base their headquarters in Singapore. Could you please start by introducing what are the main tasks and objectives of the…
clinical research Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the encouraging progress of Malaysia as an attractive place for trials since clinical research was placed under the healthcare NKEA National…
basic research The executive coordinator of GACTEC maps the current level of science and technology in Argentina and outlines the country’s ambitions in this area, which is to have an impact on innovation at the international level. When was the cabinet was founded and what exactly is its role? The Scientific Technological Cabinet…
hospital The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to become the market leader in Asia by offering a comprehensive range of services for cardiovascular medicine with a wide range…
generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…
R&D Graham Skarnvad arrived to Spain as country manager of ALK’s Spanish affiliate at the end of 2009, right when the crisis was in full swing. Later on he took the full legal responsibility – also as: General Manager for Spain, and Portugal. He discusses his mandate and increased in investment…
commercialization The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina. Could you please provide an historical overview of Argenomics? Several years ago, during my time as an employee of a multinational pharma company, I met a medical doctor and a…
See our Cookie Privacy Policy Here